Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency
A team of scientists from the University of Cambridge and the University of Cukurova in Turkey have taken a major step to understanding how the brain controls the onset of puberty. The research, published in this week’s Nature Genetics , identified the hormone Neurokinin B as a critical part of the control system that switches
Full Post: New understanding on how the brain controls onset of puberty
Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.
Results from a study by researchers at Yale School of Medicine and other institutions were presented December 6 at the Annual Meeting of the American Society of Hematology (ASH) in San Francisco.
The phase III, multi-center clinical trial focused on patients with the blood disorder known as hereditary antithrombin deficiency. Those who received the protein recombinant human antithrombin reported no excessive clotting during treatment or seven days after treatment.
“This is a remarkable technologic feat,” said study investigator Michael Paidas, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences, and director of the Women and Children’s Center for Blood Disorders at Yale. “We’ve shown that this genetically engineered protein can prevent complications linked to antithrombin deficiency. Ours is the first team in the United States to use the protein in a clinical trial with pregnant patients.”
Antithrombin occurs naturally in the body and acts as a blood thinner that signals when blood is clotting too much. Patients with antithrombin deficiency do not naturally produce antithrombin. Low antithrombin levels can result in excessive clotting, or venous thromboembolic events (VTEs), which can complicate childbirth and surgery. Those with the condition who undergo childbirth and/or surgical procedures are at high risk for pulmonary embolism-a major cause of maternal death.
The genetic deficiency affects approximately one in 2,000 to one in 5,000 people, and half of all people diagnosed suffer a thrombosis before age 25. The deficiency can also be acquired through ailments such as liver disease, malnutrition or severe burns, which can lead to impaired production of antithrombin.
Yale was one of only two U.S. sites to participate in the study, which included 18 patients-12 pregnant and six surgical. Participants with a history or risk of VTE were given an initial dose of recombinant human antithrombin, followed by maintenance doses based on antithrombin levels. The study also showed that new dosing methods could be tailored to individual patients, which helped pregnant patients to achieve and maintain ideal antithrombin levels.
If approved by the FDA, recombinant human antithrombin will be marketed under the brand name ATryn; the compound was developed by GTC Biotherapeutics and licensed to Ovation Pharmaceuticals, Inc. in the U.S.
Exciting research into blood clotting by British Heart Foundation (BHF) researchers working at the University of Bristol will take us a step closer to better heart attack prevention and treatment. Blood clots can be both life-saving and life-threatening; life-saving when they stop bleeding, but life-threatening when they form in diseased arteries feeding the heart.
Full Post: New clot-buster found
The U.S. Food and Drug Administration has licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding. People with congenital fibrinogen deficiency are unable to make sufficient amounts of fibrinogen, which plays
Full Post: FDA approves RiaSTAP for bleeding in patients with congenital fibrinogen deficiency
Investigators at Children’s Research Institute, BloodCenter of Wisconsin’s Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient’s own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can
Full Post: A new method to control bleeding in hemophilia
A review of previously published studies suggests that rates of adverse outcomes for mothers or pregnant women and newborn babies, such as gestational diabetes and low birth weight, may be lower after bariatric surgery compared with pregnant women who are obese, according to an article in the November 19 issue of JAMA, the Journal of
Full Post: Risk of maternal and newborn complications may be lower after bariatric surgery
In the battle against obesity, Yale University researchers may have discovered a new weapon - a naturally occurring molecule secreted by the gut that makes rats and mice less hungry after fatty meals. The findings are published in the Nov. 26 issue of the journal Cell . The report suggests the molecule may help regulate
Full Post: Yale researchers find molecule that may help regulate how much animals and people eat